![]() 1, 2 That enthusiasm has been coupled with growing evidence to support the benefits for medical cannabis for a variety of symptoms. The past 10 years have seen growing enthusiasm for medical cannabis in the United States, Canada, and in Europe, especially among patients with serious life-threatening conditions. The response for anxiety symptoms was not significant (OR: 1.13 95% CI: 0.77–1.64 p = 0.53), but showed an inverted U-shaped curve, with maximal benefit at a 1:1 ratio (50% THC).Ĭonclusions: These preliminary results offer a unique view of real-world medical cannabis use and identify several areas for future research. Increased THC:CBD ratio was not associated with a greater response of post-traumatic stress disorder (PTSD)-related flashbacks (OR: 1.43 95% CI: 0.60–3.41 p = 0.415) or anorexia (OR: 1.61 95% CI: 0.70–3.73 p = 0.265). Results: We included 26,150 observations between Octoand November 28, 2018. Main Outcome Measures: Self-ratings of efficacy of cannabis, defined as a three-point reduction in neuropathic pain, anorexia, anxiety symptoms, depressive symptoms, insomnia, and post-traumatic flashbacks. ![]() Participants: A total of 2,431 patients participated. Setting: This is a national Canadian patient portal. Model development used logistic regression with bootstrapped confidence intervals (CIs), with standard errors clustered to account for multiple observations by each patient. ![]() Objectives: To determine the relative contributions of tetrahydrocannabinol (THC) and cannabidiol (CBD) to patients' self-ratings of efficacy for common palliative care symptoms.ĭesign: This is an electronic record-based retrospective cohort study.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |